Phreesia (NYSE:PHR) PT Raised to $31.00

Phreesia (NYSE:PHR) had its price target upped by analysts at Truist Financial from $29.00 to $31.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective would suggest a potential upside of 31.63% from the company’s previous close.

PHR has been the topic of a number of other reports. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Thursday. DA Davidson reissued a “buy” rating and set a $32.00 target price on shares of Phreesia in a research note on Thursday. Stephens reissued an “overweight” rating and issued a $28.00 price target on shares of Phreesia in a report on Friday, May 31st. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a report on Thursday. Finally, KeyCorp reduced their target price on Phreesia from $27.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.42.

Phreesia Stock Performance

NYSE:PHR opened at $23.55 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -10.85 and a beta of 0.93. The firm’s fifty day moving average price is $23.38 and its 200 day moving average price is $22.77. Phreesia has a 1-year low of $12.05 and a 1-year high of $29.16.

Insider Transactions at Phreesia

In related news, General Counsel Allison C. Hoffman sold 14,110 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $26.03, for a total value of $367,283.30. Following the sale, the general counsel now directly owns 121,003 shares of the company’s stock, valued at approximately $3,149,708.09. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Chaim Indig sold 2,644 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total value of $62,768.56. Following the completion of the transaction, the chief executive officer now directly owns 1,219,361 shares of the company’s stock, valued at $28,947,630.14. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Allison C. Hoffman sold 14,110 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $26.03, for a total value of $367,283.30. Following the completion of the sale, the general counsel now owns 121,003 shares in the company, valued at $3,149,708.09. The disclosure for this sale can be found here. Insiders sold 29,337 shares of company stock valued at $736,750 in the last 90 days. 5.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PHR. Ensign Peak Advisors Inc boosted its stake in shares of Phreesia by 3.2% during the 2nd quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after purchasing an additional 700 shares during the last quarter. Conestoga Capital Advisors LLC boosted its position in Phreesia by 1.0% during the first quarter. Conestoga Capital Advisors LLC now owns 78,085 shares of the company’s stock worth $1,869,000 after acquiring an additional 750 shares during the last quarter. ProShare Advisors LLC grew its stake in Phreesia by 8.6% in the 1st quarter. ProShare Advisors LLC now owns 9,522 shares of the company’s stock worth $228,000 after acquiring an additional 751 shares during the period. Rhumbline Advisers grew its stake in Phreesia by 1.0% in the 2nd quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock worth $1,741,000 after acquiring an additional 853 shares during the period. Finally, Swiss National Bank raised its holdings in Phreesia by 1.0% in the 1st quarter. Swiss National Bank now owns 104,300 shares of the company’s stock valued at $2,496,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.